Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors

Journal of Controlled Release

Volumn 178, Issue 1, 2014, Pages 79-85

  Wang, Jie ^a,d   Lu, Ze ^a   Yeung, Bertrand Z ^a,b   Wientjes, M Guillaume ^a,b   Cole, David J ^c   Au, Jessie L S ^a,b,c  

^a Optimum Energy LLC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Intraperitoneal chemotherapy; Microparticles; Paclitaxel; Pancreatic cancer; Peritoneal carcinomatosis; siRNA

Indexed keywords

INTRAPERITONEAL; MICRO-PARTICLES; PACLITAXEL; PANCREATIC CANCERS; PERITONEAL CARCINOMATOSIS; SIRNA;

ANIMALS; CELL DEATH; CHEMOTHERAPY; DISEASES; LIPOSOMES; MOLECULAR BIOLOGY; PROTEINS; TUMORS; VECTOR SPACES;

DIAGNOSIS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; LIPOSOME; MESSENGER RNA; PACLITAXEL; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER TRANSPLANTATION; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GENE TARGETING; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; METASTASIS; MOUSE; NONHUMAN; PANCREAS TUMOR; PERITONEUM TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STOMACH CANCER; SURVIVAL; TUMOR XENOGRAFT;

INTRAPERITONEAL CHEMOTHERAPY; MICROPARTICLES; PACLITAXEL; PANCREATIC CANCER; PERITONEAL CARCINOMATOSIS; SIRNA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIPOSOMES; MICE; MICE, NUDE; PACLITAXEL; PERITONEAL NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893245560     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.01.012     Document Type: Article

References (53)

1. Z. Lu, M. Tsai, D. Lu, J. Wang, M.G. Wientjes, and J.L. Au Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer J. Pharmacol. Exp. Ther. 327 2008 673 682
2. M. Tsai, Z. Lu, J. Wang, T.K. Yeh, M.G. Wientjes, and J.L. Au Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel Pharm. Res. 24 2007 1691 1701 (Pubitemid 47206619)
3. M. Tsai, Z. Lu, M.G. Wientjes, and J.L. Au Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics J. Control. Release 172 2013 737 744
4. C.F. del Castillo, and L. Warshaw Peritoneal metastases in pancreatic carcinoma Hepatogastroenterology 40 1993 430 432 (Pubitemid 23310260)
5. R.L. Harmon, and P.H. Sugarbaker Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer Int. Semin. Surg. Oncol. 2 2005 3
6. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, J.A. Young, E.W. Franklin, D.L. Clarke-Pearson, V.K. Malviya, and B. DuBeshter Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N. Engl. J. Med. 335 1996 1950 1955 (Pubitemid 26428219)
7. M. Carafa, E. Santucci, and G. Lucania Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies Int. J. Pharm. 231 2002 21 32 (Pubitemid 33086815)
8. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, L.J. Copeland, J.L. Walker, and R.A. Burger Intraperitoneal cisplatin and paclitaxel in ovarian cancer N. Engl. J. Med. 354 2006 34 43 (Pubitemid 43048949)
9. A. Gadducci, F. Carnino, S. Chiara, I. Brunetti, L. Tanganelli, A. Romanini, M. Bruzzone, and P.F. Conte Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest Gynecol. Oncol. 76 2000 157 162 (Pubitemid 30067189)
10. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, L.F. Carson, S. Wadler, and J. Sickel Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J. Clin. Oncol. 19 2001 1001 1007 (Pubitemid 32176274)
11. J. Verwaal, S. van Ruth, E. de Bree, G.W. van Sloothen, H. van Tinteren, H. Boot, and F.A. Zoetmulder Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer J. Clin. Oncol. 21 2003 3737 3743 (Pubitemid 46606227)
12. H.J. Kuh, S.H. Jang, M.G. Wientjes, J.R. Weaver, and J.L. Au Determinants of paclitaxel penetration and accumulation in human solid tumor J. Pharmacol. Exp. Ther. 290 1999 871 880 (Pubitemid 29344588)
13. D. Lu, M.G. Wientjes, Z. Lu, and J.L. Au Tumor priming enhances delivery and efficacy of nanomedicines J. Pharmacol. Exp. Ther. 322 2007 80 88 (Pubitemid 46956353)
14. H.L. Wong, Z. Shen, Z. Lu, M.G. Wientjes, and J.L. Au Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures Mol. Pharm. 8 2011 833 840
15. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, and A. Ribas Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
16. J.L. Au, S.H. Jang, and M.G. Wientjes Clinical aspects of drug delivery to tumors J. Control. Release 78 2002 81 95 (Pubitemid 34081855)
17. S.H. Jang, M.G. Wientjes, D. Lu, and J.L. Au Drug delivery and transport to solid tumors Pharm. Res. 20 2003 1337 1350 (Pubitemid 37164040)
18. J. Wang, Z. Lu, M.G. Wientjes, and J.L. Au Delivery of siRNA therapeutics: barriers and carriers AAPS J. 12 2010 492 503
19. F. Li Survivin study: what is the next wave? J. Cell. Physiol. 197 2003 8 29 (Pubitemid 37486223)
20. D.S. O'Connor, D. Grossman, J. Plescia, F. Li, H. Zhang, A. Villa, S. Tognin, P.C. Marchisio, and D.C. Altieri Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin Proc. Natl. Acad. Sci. U. S. A. 97 2000 13103 13107
21. D.S. O'Connor, N.R. Wall, A.C. Porter, and D.C. Altieri A p34(cdc2) survival checkpoint in cancer Cancer Cell 2 2002 43 54
22. A.I. Sarela, C.S. Verbeke, J. Ramsdale, C.L. Davies, A.F. Markham, and P.J. Guillou Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma Br. J. Cancer 86 2002 886 892 (Pubitemid 34271023)
23. L. Sui, Y. Dong, M. Ohno, Y. Watanabe, K. Sugimoto, and M. Tokuda Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors Int. J. Oncol. 21 2002 315 320
24. G. Tonini, B. Vincenzi, D. Santini, S. Scarpa, T. Vasaturo, C. Malacrino, R. Coppola, P. Magistrelli, D. Borzomati, A. Baldi, A. Antinori, M. Caricato, G. Nuzzo, and A. Picciocchi Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients Br. J. Cancer 92 2005 2225 2232 (Pubitemid 40966261)
25. T. Tsuruma, F. Hata, T. Torigoe, T. Furuhata, S. Idenoue, T. Kurotaki, M. Yamamoto, A. Yagihashi, T. Ohmura, K. Yamaguchi, T. Katsuramaki, T. Yasoshima, K. Sasaki, Y. Mizushima, H. Minamida, H. Kimura, M. Akiyama, Y. Hirohashi, H. Asanuma, Y. Tamura, K. Shimozawa, N. Sato, and K. Hirata Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer J. Transl. Med. 2 2004 19 29
26. Y.J. Huang, W.X. Qi, A.N. He, Y.J. Sun, Z. Shen, and Y. Yao The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis Jpn. J. Clin. Oncol. 43 2013 988 995
27. M. Montorsi, M. Maggioni, M. Falleni, C. Pellegrini, M. Donadon, G. Torzilli, R. Santambrogio, A. Spinelli, G. Coggi, and S. Bosari Survivin gene expression in chronic liver disease and hepatocellular carcinoma Hepatogastroenterology 54 2007 2040 2044
28. A. Tsuburaya, Y. Noguchi, T. Yoshikawa, A. Saito, C. Doi, T. Okamoto, and K. Fukuzawa An anti-apoptosis gene, survivin and telomerase expression in gastric cancer Hepatogastroenterology 49 2002 1150 1152 (Pubitemid 34809809)
29. Z.N. Wang, H.M. Xu, L. Jiang, X. Zhou, C. Lu, and X. Zhang Expression of survivin mRNA in peritoneal lavage fluid from patients with gastric carcinoma Chin. Med. J. (Engl.) 117 2004 1210 1217 (Pubitemid 39199929)
30. H.T. Guan, X.H. Xue, Z.J. Dai, X.J. Wang, A. Li, and Z.Y. Qin Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity World J. Gastroenterol. 12 2006 2901 2907 (Pubitemid 43805461)
31. K. Kami, R. Doi, M. Koizumi, E. Toyoda, T. Mori, D. Ito, Y. Kawaguchi, K. Fujimoto, M. Wada, S. Miyatake, and M. Imamura Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells Surgery 138 2005 299 305 (Pubitemid 41253814)
32. X. Ling, R.J. Bernacki, M.G. Brattain, and F. Li Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest J. Biol. Chem. 279 2004 15196 15203 (Pubitemid 38618915)
33. S. Simoes, J.N. Moreira, C. Fonseca, N. Duzgunes, and M.C. de Lima On the formulation of pH-sensitive liposomes with long circulation times Adv. Drug Deliv. Rev. 56 2004 947 965 (Pubitemid 38520203)
34. Phase I study of intravenous DOTAP:cholesterol-Fus1 in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy, M.D. Anderson Cancer Center, http://clinicaltrials.gov/show/ NCT00059605.
35. C. Lu, D.J. Stewart, J.J. Lee, L. Ji, R. Ramesh, G. Jayachandran, M.I. Nunez, I.I. Wistuba, J.J. Erasmus, M.E. Hicks, E.A. Grimm, J.M. Reuben, V. Baladandayuthapani, N.S. Templeton, J.D. McMannis, and J.A. Roth Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans PLoS One 7 2012 e34833
36. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(- delta delta C(T)) method Methods 25 2001 402 408 (Pubitemid 34164012)
37. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63 (Pubitemid 14203433)
38. C.C. Yu, A.L. Woods, and D.A. Levison The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications Histochem. J. 24 1992 121 131
39. J.D. Kalbfleisch, and R.L. Prentice The Statistical Analysis of Failure Time Data 1980 John Wiley New York
40. D.W. Bartlett, and M.E. Davis Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging Nucleic Acids Res. 34 2006 322 333 (Pubitemid 43160055)
41. W.R. Strapps, V. Pickering, G.T. Muiru, J. Rice, S. Orsborn, B.A. Polisky, A. Sachs, and S.R. Bartz The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing Nucleic Acids Res. 38 2010 4788 4797
42. Y. Lei, Z. Geng, W. Guo-Jun, W. He, and Y. Jian-Lin Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance Mol. Cell. Biochem. 344 2010 23 31
43. F. Rodel, T. Sprenger, B. Kaina, T. Liersch, C. Rodel, S. Fulda, and S. Hehlgans Survivin as a prognostic/predictive marker and molecular target in cancer therapy Curr. Med. Chem. 19 2012 3679 3688
44. N. Zaffaroni, M. Pennati, G. Colella, P. Perego, R. Supino, L. Gatti, S. Pilotti, F. Zunino, and M.G. Daidone Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer Cell. Mol. Life Sci. 59 2002 1406 1412
45. S. Akhtar, and I.F. Benter Nonviral delivery of synthetic siRNAs in vivo J. Clin. Invest. 117 2007 3623 3632 (Pubitemid 350224068)
46. Y.K. Oh, and T.G. Park siRNA delivery systems for cancer treatment Adv. Drug Deliv. Rev. 61 2009 850 862
47. Y.C. Tseng, S. Mozumdar, and L. Huang Lipid-based systemic delivery of siRNA Adv. Drug Deliv. Rev. 61 2009 721 731
48. Y. Li, J. Wang, Y. Gao, J. Zhu, M.G. Wientjes, and J.L. Au Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability AAPS J. 13 2011 585 597
49. J.P. Muller, B.S. Aytar, Y. Kondo, D.M. Lynn, and N.L. Abbott Incorporation of DOPE into lipoplexes formed from a ferrocenyl lipid leads to inverse hexagonal nanostructures that allow redox-based control of transfection in high serum Soft Matter 8 2012 2608 2619
50. A. Santel, M. Aleku, O. Keil, J. Endruschat, V. Esche, G. Fisch, S. Dames, K. Loffler, M. Fechtner, W. Arnold, K. Giese, A. Klippel, and J. Kaufmann A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium Gene Ther. 13 2006 1222 1234 (Pubitemid 44184716)
51. R.H. Stauber, W. Mann, and S.K. Knauer Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential Cancer Res. 67 2007 5999 6002 (Pubitemid 47037475)
52. J. Patel Drug combination extends late-stage pancreatic cancer survival in phase III clinical trial Expert. Rev. Clin. Pharmacol. 6 2013 100
53. K. Kami, R. Doi, M. Koizumi, E. Toyoda, T. Mori, D. Ito, K. Fujimoto, M. Wada, S. Miyatake, and M. Imamura Survivin expression is a prognostic marker in pancreatic cancer patients Surgery 136 2004 443 448 (Pubitemid 39037686)